News

PMLive3h
Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...
StockStory.org on MSN10h
The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call
Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...
Medical Dialogues23h
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...